A Study of Effect of Megakaryocytes and Platelets in Breast Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- La Crosse, Wisconsin: 23-004958
NCT ID: NCT06011824
Sponsor Protocol Number: 23-004958
About this study
The purpose of this study is to determine how megakarocytes (cells in the bone marrow responsible for making platelets, which are necessary for blood clotting) affect the survivial and growth/division patterns of breast cancer stem cells, and the effects of breast cancer cells on megakatocyte survival and function. Through chart review, the study team will look at the relationship different blood components and different breast cancer diagnosis.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Cohort 1-Biopsy negative
-Females age 18 and above
Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other)
* Females age 18 and above
* Any subtype of breast cancer
Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
* Females age 18 and above
* Any subtype of breast cancer
* Have no distant metastases
Cohort 4-Stage 4 Metastatic Disease
* Females age 18 and above
* Any subtype of breast cancer
Exclusion Criteria:
Cohort 1-Biopsy negative
* Males
* Females less than age 18
Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other)
* Males
* Females less than age 18
* Currently undergoing neoadjuvant therapy
Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
* Males
* Females less than age 18
* Presence of distant metastases
* Currently undergoing neoadjuvant therapy
Cohort 4-Stage 4 Metastatic Disease
* Males
* Females less than age 18
* Currently undergoing neoadjuvant therapy
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 7/17/2024. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
More information
Publications
Publications are currently not available